Proteins

Product Data Sheet

VU0152099

Cat. No.: HY-119226 CAS No.: 612514-42-8 Molecular Formula: $C_{18}H_{17}N_3O_3S$

Molecular Weight: 355.41 mAChR Target:

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: 4°C, protect from light

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 12.5 mg/mL (35.17 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8137 mL	14.0683 mL	28.1365 mL
	5 mM	0.5627 mL	2.8137 mL	5.6273 mL
	10 mM	0.2814 mL	1.4068 mL	2.8137 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (3.52 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (3.52 mM); Clear solution

BIOLOGICAL ACTIVITY

Description VU0152099 is a potent, selective and brain-penetrant mAChR M4 positive allosteric modulator with an EC₅₀ of 0.4 μM for rat M4 receptor. VU0152099 is inactive for other mAChR subtypes or other GPCRs. VU0152099 has no agonist activity but potentiated responses of M4 to acetylcholine^[1].

In Vitro

VU0152099 (30 μM) induces a dose-dependent leftward shift of the acetylcholine (ACh) concentration response curve (CRC) with maximal shifts of 30-fold observed with 30 μM. VU0152099 dose-dependently potentiates the response to an EC20 concentration of ACh with EC $_{50}$ values of 1.2 μ M, and increases the maximal response to ACh to approximately 130%. VU0152099 is a potent positive allosteric modulator that enhance the response of the M4 receptor to the endogenous agonist ACh^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

 $\label{eq:VU0152099} \textit{(56.6 mg/kg; i.p.; once)} \ \textit{reverses Amphetamine-induced hyperlocomotion in rats} \\ [1].$

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (270-300 g) injected with Amphetamine ^[1]	
Dosage:	56.6 mg/kg	
Administration:	i.p.; once	
Result:	Reversed Amphetamine-induced hyperlocomotion in rats.	

REFERENCES

[1]. Ashley E Brady, et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther. 2008 Dec;327(3):941-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA